Lupus support   40 Jahre Leben mit Lupus Lupus-Selbsthilfe
Home Home English   About Lupus About Lupus   Immune System   Autoimmune Diseases   Rhumatism   Diagnosis   Diagnostic odysseys   Involvement of Organs   Blood tests   Intimacy and Pregnancy   Treatment   Research
Doctors Doctors   Links Links English   The German Lupus Book The German Lupus Book English   Books/Videos/Media Books/Videos/Media   Lupus Support Group Lupus Support Group   Forums Forums   Events Events   Questions and Answers Questions and Answers   Sjögren-Selbsthilfegruppe Darmstadt, Rheuma-Liga Hessen e. V. Sjögren-Informationen   About this Web Site About this Web Site   News News


About Lupus erythematosus


Are you sometimes tired and tense without knowing why?
Do you sometimes have pains in the joints or in the limbs?
Do you sometimes feel nauseated?
Do you have a noticeable hair loss?
Do you have headaches?
Do you feel run down although you sleep a lot?
Do you occasionally have a very dry mouth and eyes? Do you have conjunctivitis?
Do you sometimes have an increased temperature or an unexplainable fever?
Do you occasionally have a "butterfly" rash over the cheeks of the face or patchy redness on other parts of your body?
Are you sensitive to light and can no longer cope with direct sunlight?
Have you visited many doctors searching for advice and none of them had answers for you?

If you answer three or four of the above questions with "yes", it could be possible that you have a disease that is known as "Lupus erythematosus". Further symptoms or conditions that can also occur are for example heart, lung or kidney abnormalities, diarrhoea, problems to concentrate, convulsions and psychic disorders.

What is Lupus?

Lupus erythematosus is an autoimmune disease, which belongs to the inflammatory rheumatic conditions and thereby to the connective tissue diseases. There are two main forms of lupus: Cutaneus lupus erythematosus and systemic lupus erythematosus (SLE).

Cutaneus lupus erythematosus

Some of the patients only have an involvement of the skin. There are different sub forms of cutaneus lupus. The most frequent form ist the discoid lupus erythematosus (DLE). It is characterised by discoid shaped, squamous red rashes on the face or other parts of the body. In approximately five to ten percent of these patients, the cutaneus lupus develops into a systemic lupus erythematosus.

Systemic lupus erythematosus (SLE)

This is the most frequent form of lupus. There can be an involvement of the skin, the joints and internal organs. The typical skin rash on the cheeks (often in a butterfly shape) occurs only in less than half of the SLE-patients.

Most common symptoms of people with systemic lupus erythematosus:

Symptoms of SLE

Frequency (in percent)

Joint pain 85
Generalised condition of fatigue, weakness 84
Changes of the skin ("butterfly" rash, patchy redness, skin rash) 81
Kidney problems 77
Arthritis 63
Raynaud-Syndrom (fingers and toes get cold and discolour bluish, blanching, generally accompanied with pain) 58
Disorders of the central nervous system 54
Changes or disorders of the mucous membranes 54
Disorders of the digestive system 47
Pleurisy 37
Disease of the lymphatic nodes 32
Pericarditis (inflammation of the membraneous sac around the heart) 29
Lung disorders 17
Myositis (inflammation of the muscles)   5
Myocarditis (inflammation of the cardiac muscle)   4
Pancreatitis   4

(The above list is taken from: Hettenkofer, Hans-Jürgen [Ed.]: Rheumatologie. Stuttgart: Thieme Verlag, 1998, p. 91)


Factors that can trigger lupus erythematosus

Eighty percent of the patients with systemic lupus erythematosus are young women between 15 and 45. Lupus has in fact something to do with the female hormones (estrogenes). Quite often Lupus is triggered off during or after a pregnancy. The intake of the "pill" (contraceptives containing estrogen) can stimulate the disease. Also noticeable problems and irregularities (such as joint pains) correlated to the menstrual periods could be an indication of lupus.

Sensitiveness to sunlight is also typical of lupus. Sunlight can stimulate and worsen the disease progression. This is the reason, why lupus sometimes breaks out after sunbathing or a holiday in a sunny climate. Like other autoimmune diseases, physical and psychical stress influences the disease and its progression in a negative manner. Certain foods and medication can intensify disease activitiy.

Up to date, the cause of the disease is unknown. It is thought that similar to other autoimmune diseases, a genetic disposition together with other factors trigger the disease off. Certain prescribed drugs can induce symptoms similar to those of systemic lupus erythematosus (drug-induced lupus erythematosus). Usually the symptoms fade when the drug use is discontinued.

Diagnosis

Often it takes a long time until the diagnosis lupus erythematosus is found. The reason is that patients have a wide variety of symptoms and different combinations of involvement. In cases involving purely cutaneous complaints, a biopsy of the skin lesions points toward the diagnosis. According to the 2012 published criteria of the American Rheumatism Association, four of seventeen findings must be given to consider the possibility of systemic lupus erythematosus (so called "SLICC-criteria"). A prooved involvement of internal organs is no essential criteria for the diagnosis "SLE". It is not possible to make the diagnosis of SLE in early phases of the disease by using the SLICC-Criteria. According to the EULAR criteria published in 2019, antinuclear antibodies (ANA) serve as an important entry criterion for the diagnosis of SLE. However, due to suboptimal laboratory methods, they cannot always be detected - even in rheumatology practices (documented cases exist)! Therefore, if SLE is suspected, it is advisable to have the testing performed by a laboratory that specializes in immunological diseases, such as Labor Volkmann in Karlsruhe.

It is more difficult to make the diagnosis "Lupus" in cases of chronic progressive course of disease than in cases of intermittend disease progression (see below).

Due to the fact that lupus is a relatively seldom disease, it remains unknown to many doctors. In Germany, there are only approximately 30 - 40.000 people who suffer from SLE. Doctors can therefore not readily recognise the disease. Many young women are considered to be a hypochondriac.

The doctor for the diagnosis and treatment of lupus is a specialist for internal diseases, who has also specialised in rheumatology. It is possible to identify the disease through particular blood tests, first of all the antinuclear antibody (ANA) test and further antibody tests as for example the DNA antibody test.

Quite often, when the symptoms and blood tests show no clear indication for an exact diagnosis, the diagnosis that is then first given is "undifferentiated connective tissue disease". The treatment is the same. There are also a variety of mixed disease forms between LE and other connective tissue diseases such as Sjogren's syndrome, Scleroderma and the antiphospholipid antibody syndrome.

Course of disease

The progression of the illness in approximately two thirds of the lupus patients is intermittent. About half of these patients have in between the periods of disease activity (flares) little to no ailment (remission) whereas the other half experience continuing activity in between the major periods of disease activity (partial remission).

Approximately a third of the patients have a chronic progressive course of disease, i.e. the disease progressions continually developing slowly, without periods of major activity and non-activity.

Disease activity

To date there are no blood tests available to measure the disease activity. Neither the blood sedimentation nor the amount (titre) of the antinuclear antibody (ANA) test directly reflects the disease activity. The C-reactive protein (CRP) is in fact during a major activity period only slightly raised. It seems that the raise of the DNA antibody titre and a reduction of the complement indicates an increased disease activity.

However, all of these aforementioned laboratory values can be within the normal range, even though disease activity may still be increasing. To reliably assess disease activity, it is necessary to consider a combination of the patient's symptoms, clinical findings, and laboratory test results. According to the new European lupus guidelines and the 2025 German lupus guidelines , this assessment utilizing disease activity scores such as ECLAM, SLEDAI, or BILAG should be performed at every medical appointment.

When a patient's symptoms from the preceding month are accurately captured and entered into these scoring systems, the resulting scores provide a highly reliable and valid representation of disease activity. These scores correlate with one another and serve as an invaluable tool for gaining a precise overview of the disease. They are also well-suited for the ongoing self-monitoring of the condition by patients. In this way, the technical methods used to evaluate lupus disease activity are becoming more closely aligned with the actual clinical presentation of the illness. Hopefully, this will finally put an end to the all-too-common scenario where lupus patients - despite being clearly unwell - are told by their rheumatologist that their condition cannot be active because their erythrocyte sedimentation rate (ESR) is not elevated, anti-dsDNA antibodies are absent, or complement levels have not decreased. Regrettably, even in the short time since the publication of the new lupus guidelines, a case has come to light involving a German nephrologist specializing in rheumatology who filled out a score as "zero" falsely, as she had not even questioned the patient and subsequently questioned the validity of lupus disease activity scores during a consultation. The physician's name is known, and the medical report is available for review should any questions arise. It is to be hoped that this remains an isolated incident; after all, why would various research groups have invested over 20 years of effort into developing these lupus disease activity scores if they were not intended to be used properly?

Treatment

Cutaneous lupus is treated with hydroxychloroquine, corticosteroid ointments, and if these prove insufficient with "reserve" medications such as dapsone. For the treatment of systemic lupus erythematosus, the new European lupus guidelines prescribe a regimen that calls for the early use of more potent immunomodulatory drugs. The objective is to reduce both disease activity and corticosteroid consumption to strictly defined target levels. The "wait-and-see" approach historically common in rheumatology, where stronger medications were reserved for cases involving significant internal organ involvement has thus been definitively abandoned in the context of lupus, for the benefit of the patients affected. The following medications are used:

Painkillers as Non-steroidal Anti-inflammatory Drugs (NSAID)

Antimalarials (e.g. chloroquine, hydroxychloroquine)

Immunosuppressants (e.g., azathioprine, ciclosporin A, mycophenolate mofetil) and biologics, such as the monoclonal antibodies anifrolumab and belimumab

Cytotoxic drugs (e.g. methotrexate, cyclophosphamide)

Various medications used off-label that is, outside the scope of their formal marketing authorization such as rituximab, infliximab, baricitinib, and sarilumab (to name a few)

CAR-T cell therapy is being used on an experimental basis; in some patients, it has led to treatment-free remission lasting several years, though it can also be associated with severe side effects and is very expensive.

In parallel, cortisone (e.g., prednisone, prednisolone, Lodotra®) is administered at all stages.

This list starts with the weaker and ends with the stronger medications. The choice of medication depends on the seriousness of the clinical symptoms. Antimalarials have been found to be particularly effective in working against lupus erythematosus skin and joint problems. If disease activity is not sufficiently brought under control with this, immunosuppressants, biologics, and cytostatics are used. The purpose of the use of these medications is to decrease inflammation and the level of autoimmune activity in the body. The medications intervene in the various locations of the disease process, however a causal treatment that brings permanent cure is with the exception of CAR-T cell therapy to date not available.

Patients with intermittent disease progression react generally better to the treatment of the known medication than the patients with a chronic progressive course of disease.

The earlier the treatment starts, the better the course of the disease can be influenced. Today, lupus patients can expect a normal life expectancy if the disease is recognised and treated early after its outbreak. The quality of life may be reduced in one way or the other.

Future

For several years, medical and pharmaceutical research has also focused on developing new treatment approaches for "typical" (or average-presentation) lupus. With the approval of anifrolumab in market launch 2022, a new medication has reached the market that benefits a large number of patients with such "typical" disease courses. It is to be hoped that further medications will be developed for these "typical" cases. The requirement for a positive ANA (antinuclear antibody) test as a prerequisite for further lupus diagnostic workups should be abandoned, as even today, not all rheumatology practices have access to laboratory methods capable of detecting existing ANAs. Furthermore, a definitive, universally accepted definition of a "lupus flare" is still lacking. Completed disease activity scores should be attached to every clinical report and leveraging artificial intelligence automatically integrated into a patient's lupus treatment plan.



New european Lupus guideline 2023/2024: Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83:15-29. https://ard.bmj.com
Commentary: The European guideline, updated in 2023, represents a milestone in the diagnosis and treatment of systemic lupus. Binding for all rheumatologists in Europe, it should be promptly incorporated into clinical practice by all rheumatologists.

Commentary on the new European lupus guideline on Reddit https://www.reddit.com

AWMF: Neue deutsche Leitlinie Systemischer Lupus erythematodes, 2025 https://register.awmf.org
Commentary: The first German lupus guideline, published in 2025, is aligned in its key aspects with the European lupus guideline released in 2023/2024.

AWMF: Neue Leitlinie Systemischer Lupus erythematodes mit Beginn im Kindes- und Jugendalter (jSLE), 2025 https://www.awmf.org

Lupus UK https://www.lupusuk.org.uk/

The British Sjögren's Syndrome Association www.bssa.uk.net

The Lupus Site https://www.thelupussite.com/

dict.cc https://www.dict.cc/

LEO https://dict.leo.org/



Many thanks to an australian scleroderma patient and Google Translator for the English translation.



(Last modified: 18.11.2026)



Faces of Lupus - If you click on this picture, you will see that lupus patients are people just like you and me!



The author reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided: https://www.disclaimer.de.


Top


Contact:
Dipl.-Psych. Dorothea Maxin - Gervinusstr. 47, D-64287 Darmstadt - Germany - Kontakt